Novogen Ltd. engages in the pharmaceutical drug development. It involves in preclinical research confirms efficacy of cantrixil which induces cell death in chemoresistant ovarian cancer stem cells. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Hornsby, Australia.
|Market Price at 20-11-2017||$0.35|
|Price to Earnings Ratio||-2.19|
|Market Capitalisation||$171.57 (million)|
|Return on Equity (ROE)||-43.13%|